AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21831926
Drug: Stay active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stay active care, muscle stretching, manual therapy and steroid injections (group 4)
Trial: 18298230
Drug: Integrated cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated cognitive‐behavioral therapy
Trial: 18298230
Drug: 12‐step facilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12‐step facilitation therapy
Trial: 17038946
Drug: Polyester collagen-coated
RxNorm normalized name: polyester-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyester collagen-coated vascular patch
Trial: 10368454
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of rickets
Trial: 10368454
Drug: Echocardiographic studies
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Echocardiographic studies before treatment
Trial: 10368454
Drug: Echocardiographic studies
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Echocardiographic studies after treatment
Trial: 8763050
Drug: Minaprine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minaprine (200 mg/d)
Trial: 26922669
Drug: Synthetic cartilage
RxNorm normalized name: SHARK CARTILAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic cartilage implant
Trial: 24035770
Drug: 5-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-day regimen of antibiotics after catheter exchange
Trial: 24035770
Drug: 10-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-day regimen of antibiotics with catheter retention
Trial: 21118681
Drug: Acarbose after
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose after 7 months of therapy
Trial: 20344882
Drug: Radio Electric
RxNorm normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radio Electric Asymmetric Treatment (REAC)
Trial: 15628696
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg sKET
Trial: 15628696
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg sKET
Trial: 11270028
Drug: Hydroxyzine 1
RxNorm normalized name: hydroxyzine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine 1 mg kg‐1
Trial: 8348281
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 5 mg
Trial: 8348281
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) doses ranging from 5 to 20 mg
Trial: 12014167
Drug: Placebo agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo agent
Trial: 23162576
Drug: Aloe vera
RxNorm normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloe vera gel (A.V. 2% oral gel)
Trial: 18543329
Drug: Tetracycline (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline (500 mg orally twice a day for 28 days)
Trial: 15910187
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) + Pulsed Dye Laser (PDL)
Trial: 1872042
Drug: Felbinac Gel
RxNorm normalized name: felbinac
DrugBank: Felbinac (DB07477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felbinac Gel 3% (1 g, three times daily)
Trial: 29103065
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise intervention (2 weekly sessions for 12 months)
Trial: 25800784
Drug: TDF monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF monotherapy (300 mg/day)
Trial: 25800784
Drug: TDF and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF and ETV combination therapy (TDF 300 mg/day and ETV 1 mg/day)
Trial: 24827808
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m² on days 21, 28, 35, 42, 175, 182, 189, and 196)
Trial: 22751980
Drug: Combined anticoagulant-aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined anticoagulant-aspirin therapy (100-mg prophylactic dose)
Trial: 22751980
Drug: Aspirin therapy
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin therapy (100-mg prophylactic dose)
Trial: 18309485
Drug: S-1 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 treatment
Trial: 17035614
Drug: 30 mEq
RxNorm normalized name: Rum-K, 30 mEq/15 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mEq of oral potassium citrate (Kcitrate)
Trial: 17035614
Drug: Both K
RxNorm normalized name: Effer-K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both K supplements
Trial: 11085844
Drug: Sexual dysfunction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sexual dysfunction treatments
Trial: 10945508
Drug: Cefaclor 250
RxNorm normalized name: cefaclor 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 250 mg TID
Trial: 18716314
Drug: Generic enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic enoxaparin (40 mg, single-dose subcutaneous administration)
Trial: 10550150
Drug: Gemcitabine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,000 mg/m² on days 1, 8, and 15 plus cisplatin 100 mg/m² on day 2, every 28 days
Trial: 10550150
Drug: Mitomycin 6
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin 6 mg/m², ifosfamide 3,000 mg/m², and mesna on day 1 plus cisplatin 100 mg/m² on day 2, every 28 days
Trial: 378732
Drug: Butorphanol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol (1 mg and 2 mg)
Trial: 378732
Drug: Meperidine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (40 mg and 80 mg)
Trial: 30556911
Drug: 2% tofacitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% tofacitinib ointment applied twice daily for 4 weeks
Trial: 26605849
Drug: Gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene therapy with subretinal delivery of a recombinant adeno‐associated viral vector carrying RPE65
Trial: 19547808
Drug: Clozapine (n=115,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (n=115, 75-600 mg)
Trial: 19547808
Drug: Haloperidol (n=105,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (n=105, dose range 2-15 mg)
Trial: 19547808
Drug: Chlorpromazine (n=105,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (n=105, 100-400 mg)
Trial: 8879890
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg PO QD, titrated to 50 mg losartan/12.5 mg HCTZ PO QD after 4 weeks, then to 50 mg losartan/25 mg HCTZ PO QD after 8 weeks)
Trial: 8879890
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 mg PO QD, titrated to 10 mg PO QD after 4 weeks, then to 10 mg plus 25 mg HCTZ PO QD after 8 weeks)
Trial: 6465669
Drug: Inhaled vasoactive
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled vasoactive intestinal peptide (VIP) 100 micrograms
Trial: 6465669
Drug: Control solution
RxNorm normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control solution (1% human serum albumin in 2 ml 0.9% saline)
Trial: 26875905
Drug: Shock wave
RxNorm normalized name: ELECTRODE GEL,H-WAVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shock wave therapy (SW group)
Trial: 24824095
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (nonweight bearing and early range of motion exercise)
Trial: 20716300
Drug: Treatment addressing
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment addressing anxiety symptoms
Trial: 16294506
Drug: New nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: New nevirapine tablet formulation (test, T)
Trial: 16294506
Drug: Reference nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference nevirapine tablet formulation (R)
Trial: 11923816
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (bemiparin sodium 3500 IU/daily subcutaneously)
Trial: 7577777
Drug: 0.5% plain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% plain bupivacaine followed by a continuous infusion of 7 mL/h 0.25% bupivacaine
Trial: 2122869
Drug: Amiodarone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (200 mg/day after impregnation)
Trial: 2122869
Drug: Placebo phase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo phase (2 weeks) followed by 6 weeks of active treatment
Trial: 31791239
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine at 1 μg·kg‐1
Trial: 31791239
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline at 0.01 ml·kg‐1
Trial: 28932090
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (400 mg) HL tablet
Trial: 28932090
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (133.4 mg) HL tablet
Trial: 15285274
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Codonopsis pilosula (CPG) and Gingko biloba (GB)
Trial: 11583941
Drug: Sirolimus at
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus at 2 mg/d
Trial: 11583941
Drug: Sirolimus at
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus at 5 mg/d
Trial: 11583941
Drug: Sirolimus (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (both doses)
Trial: 786045
Drug: THC (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (20 mg) in fast condition
Trial: 786045
Drug: THC (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (20 mg) in slow condition
Trial: 786045
Drug: Alcohol (intoxicating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (intoxicating doses)
Trial: 25746966
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid (budesonide)
Trial: 21627766
Drug: Gabapentin enacarbil
RxNorm normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin enacarbil (GEn) 1,200 mg (624 mg-equivalents gabapentin), twice daily for 14 days
Trial: 21627766
Drug: Gabapentin capsules
RxNorm normalized name: Gabapentin Capsules
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin capsules
Trial: 22157410
Drug: Non-CABG (percutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-CABG (percutaneous coronary intervention plus medical treatment)
Trial: 16507375
Drug: CSDVC (clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSDVC (clindamycin phosphate 2% single-dose vaginal cream)
Trial: 16507375
Drug: CVC (7-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVC (7-day regimen of clindamycin phosphate 2% vaginal cream)
Trial: 12869610
Drug: Melatonin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (3 mg tablet)
Trial: 10219129
Drug: Brånemark, IMZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brånemark, IMZ or Frialit‐2 endosseous implants with autogenous bone grafts
Trial: 10219129
Drug: Oral implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral implants in periodontally healthy patients
Trial: 25456960
Drug: Control (Standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Standard postoperative analgesic treatment with acetaminophen)
Trial: 23364039
Drug: Recreational combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recreational combination gymnastics program (conducted twice a week for 12 weeks)
Trial: 20425851
Drug: Tobramycin solution
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin solution for inhalation (TSI), 5 ml nebulized treatment twice a day for 28 days (one cycle), followed by 28 days off, for three cycles.
Trial: 15739091
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml saline (group 1, n=18)
Trial: 8590488
Drug: Ketamine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (2 mg.kg‐1)
Trial: 8590488
Drug: Midazolam (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.3 mg.kg‐1)
Trial: 1967418
Drug: Low-dose bradykinin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose bradykinin infusion (30 ng/kg per min)
Trial: 1967418
Drug: Chronic bradykinin
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic bradykinin administration (6 days)
Trial: 279137
Drug: 0.5% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% sodium fluoride solution (weekly mouth-rinsings)
Trial: 31931509
Drug: Nicotine (2-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (2-mg lozenge)
Trial: 25889057
Drug: Cognitive tests
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive tests administered in a familiar environment (Familiar cohort)
Trial: 25889057
Drug: Cognitive tests
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive tests administered in a foreign environment (Foreign cohort)
Trial: 22007904
Drug: Adapalene gel
RxNorm normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adapalene gel and nadifloxacin cream
Trial: 17668527
Drug: Adapalene gel
RxNorm normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adapalene gel monotherapy
Trial: 19797187
Drug: Telmisartan (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (80 mg/d)
Trial: 16825271
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium 15 mmol twice daily (n = 28)
Trial: 9862830
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 infusion (0, 0.375, 0.75, and 1.5 pmol/kg/min)
Trial: 9862830
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 infusion (highest dose)
Trial: 8549029
Drug: Atovaquone (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atovaquone (750 mg every 12 hours)
Trial: 1834003
Drug: Warfarin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin and Aspirin
Trial: 6800440
Drug: Preseasonal hyposensitisation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preseasonal hyposensitisation treatment with an aqueous rye extract
Trial: 26697176
Drug: Ranolazine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine (500 mg, uptitrated to 1,000 mg at week 4)
Trial: 23452432
Drug: Prediction model
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prediction model for OTC-medication use based on maternal characteristics
Trial: 19479489
Drug: Estradiol 0.014
RxNorm normalized name: ESTRADIOL 0.014MG/DAY (MENOSTAR) PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol 0.014 mg/day
Trial: 9759389
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (0.02 mg/ml, three times daily for 5 days)
Trial: 9759389
Drug: Thio-tepa (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thio-tepa (four times daily for 6 weeks)
Trial: 9759389
Drug: Distilled water
RxNorm normalized name: Distilled Water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distilled water (three times daily for 5 days)
Trial: 26171392
Drug: Intra-articular bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular bupivacaine combined with intravenous parecoxib
Trial: 26171392
Drug: Intravenous parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Intravenous parecoxib monotherapy (control group)
Trial: 23919274
Drug: Celecoxib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg twice daily) and UDCA (1000-2000 mg daily, 20-30 mg/kg/day)
Trial: 2138925
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic treatment (Control)
Trial: 18375998
Drug: Abciximab infusion
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab infusion
Trial: 27327862
Drug: High-dose bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose bolus tirofiban
Trial: 12113544
Drug: Gabexate mesilate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabexate mesilate (GM), 2.0 mg/kg/hr, administered intravenously starting 24 hours before surgery until postoperative day 3 (preop GM group)
Trial: 12113544
Drug: Gabexate mesilate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabexate mesilate (GM), administered at the beginning of surgery (intraop GM group)
Trial: 2368745
Drug: Drug-use review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-use review (DUR) program intervention
Trial: 29653652
Drug: Betrixaban (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betrixaban (80 mg)
Trial: 22464802
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet + supplement
Trial: 17901014
Drug: Occupation-focused, client-centered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupation-focused, client-centered occupational therapy
Trial: 2087329
Drug: Needle acupuncture
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle acupuncture (stainless steel needles at point Hegu (L.I.4) on both sides)
Trial: 2087329
Drug: Laser acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser acupuncture (helium-neon laser at points Hegu (L.I.4) and Jianqian (Extra.) on both sides for 1 min)
Trial: 390674
Drug: Tiaprofenic acid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiaprofenic acid, 200 mg three times a day
Trial: 390674
Drug: Ibuprofen, 400
RxNorm normalized name: Ibuprofen, 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen, 400 mg three times a day
Trial: 31568698
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein isolate (WPI) supplementation (20 g/d) for 3 months
Trial: 24389453
Drug: Sacha inchi
RxNorm normalized name: Abies sachalinensis var. sachalinensis oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacha inchi oil (10 or 15ml daily)
Trial: 24389453
Drug: Sunflower oil
RxNorm normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower oil (10 or 15ml daily)
Trial: 22968159
Drug: Nebulized hypertonic
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized hypertonic saline solution alone
Trial: 19560158
Drug: Thimerosal-containing vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thimerosal-containing vaccines
Trial: 15850499
Drug: Isradipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (30 mg SR at bedtime, plus 15 mg IR administered 2 h before methamphetamine infusion)
Trial: 8735556
Drug: Vi capsular
RxNorm normalized name: typhoid vaccine VI capsular polysaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi capsular polysaccharide vaccine
Trial: 9987143
Drug: Meningococcal A
RxNorm normalized name: MENINGOCOCCAL A/B/C/W/Y (PENBRAYA) KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal A + C control vaccine
Trial: 1692602
Drug: Intranasal interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal interferon
Trial: 19535229
Drug: Sublingual orally
RxNorm normalized name: Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual orally disintegrating olanzapine (ODO)
Trial: 17280773
Drug: Desmopressin (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin (0.1, 0.2, or 0.4 mg)